Analyst Consensus Predictions for The Coca-Cola Co (NYSE:KO), Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

SHARE

Wall Street sell-side research analysts covering The Coca-Cola Co (NYSE:KO) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $46.272 on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $51 while the most conservative estimate stand at $40.

Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover The Coca-Cola Co. They give the company shares an ABR of 2.5. This is based on the 11 analysts taken into consideration by Zacks.

Earnings Estimates for The Coca-Cola Co (NYSE:KO)

Currently, Wall Street is projecting that the firm will post $0.37 earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on 2016-09-30, The Coca-Cola Co's EPS was reported as $0.49. This created a “surprise factor” 2.08% due to being $0.01 apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.

Investors will mark their calendars for 2017-02-14, the date when The Coca-Cola Co (NYSE:KO) are expected to release their quarterly results.

Wall Street sell-side research analysts covering Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $31.384 on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $50 while the most conservative estimate stand at $22.

Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover Valeant Pharmaceuticals International, Inc.. They give the company shares an ABR of 2.89. This is based on the 13 analysts taken into consideration by Zacks.

Earnings Estimates for Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Currently, Wall Street is projecting that the firm will post $1.56 earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on 2016-09-30, Valeant Pharmaceuticals International, Inc.'s EPS was reported as $1.55. This created a “surprise factor” -12.92% due to being $-0.23 apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.

Investors will mark their calendars for 2017-03-21, the date when Valeant Pharmaceuticals International, Inc. (NYSE:VRX) are expected to release their quarterly results.

LEAVE A REPLY